A Competing Risk Analysis of Cancer-Specific Mortality of Initial Treatment with Radical Prostatectomy versus Radiation Therapy in Clinically Localized High-Risk Prostate Cancer

Annals of Surgical Oncology

Volumn 21, Issue 12, 2014, Pages 4026-4033

  Lee, Joo Yong ^a   Cho, Kang Su ^b   Kwon, Jong Kyou ^a   Jeh, Seong Uk ^a   Kang, Ho Won ^a   Diaz, Richilda Red ^a   Ham, Won Sik ^a   Koom, Woong Sub ^a   Keum, Ki Chang ^a   Choi, Young Deuk ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CAUSE OF DEATH; CHARLSON COMORBIDITY INDEX; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PELVIS LYMPHADENECTOMY; PROPENSITY SCORE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RADIATION DOSE; RISK ASSESSMENT; TREATMENT DURATION; CANCER GRADING; COMPARATIVE STUDY; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

AGED; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM GRADING; PROGNOSIS; PROPENSITY SCORE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 84918801838     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3780-9     Document Type: Article

References (33)

1. Abdollah F, Suardi N, Cozzarini C, et al. Selecting the optimal candidate for adjuvant radiotherapy after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol. 2013;63:998–1008.
2. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate cancer: from definition to contemporary management. Eur Urol. 2012;61:1096–106.
3. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol. 2014;65:124–37.
4. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–31.
5. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10:1081–7.
6. Van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol. 2008;53:253–9.
7. Hoffman RM, Koyama T, Fan KH, et al. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst. 2013;105:711–8.
8. Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28:1508–13.
9. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400–9.
10. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
11. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52:249–64.
12. Rubin DB. On principles for modeling propensity scores in medical research. Pharmacoepidemiol Drug Saf. 2004;13:855–7.
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.
14. Goldberg H, Baniel J, Yossepowitch O. Defining high-risk prostate cancer. Curr Opin Urol. 2013;23(4):337–41.
15. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–92.
16. D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163–72.
17. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003;169:157–63.
18. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80.
19. Sundi D, Jeong BC, Lee SB, Han M. Optimizing the management of high-risk, localized prostate cancer. Korean J Urol. 2012;53:815–20.
20. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol. 2005;173:1557–61.
21. Joniau S, Tosco L, Briganti A, et al. Results of surgery for high-risk prostate cancer. Curr Opin Urol. 2013;23(4):342–8.
22. Qin X, Ye D. Re: Jutta Engel, Patrick J. Bastian, Helmut Baur, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010;57:754–61. Eur Urol. 2010;58(4):e43; author reply e44.
23. Qin XJ, Ma CG, Ye DW, et al. Tumor cytoreduction results in better response to androgen ablation: a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol. 2012;30:145–9.
24. Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol. 2000;163:1085–9.
25. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329–35.
26. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924–30.
27. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–27.
28. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116:5226–34.
29. Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117:2883–91.
30. Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA. Radical prostatectomy for clinical T4 prostate cancer. Cancer. 2006;106:2603–9.
31. Westover K, Chen MH, Moul J, et al. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU Int. 2012;110:1116–21.
32. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys. 2005;61:1019–34.
33. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–500.